leisure time -WSS

leisure time

author：fashion 2025-09-29 18:59:39 - browse：77616

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What it’s like to watch children die of measles

WSS

Amylyx ALS drug failure raises questions and concerns

Kellogg’s is going to war over Mexico’s nutrition label rules

Hospital at home shows how to bring innovation to health care

DeSantis wants to import drugs. Biden’s FDA blasted his plan

FDA greenlights medical device to combat bladder issues

Change Healthcare payments predicted restored March 15

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PBMs are inflating the cost of generic drugs. They must be reined in

Novavax promises a turnaround & Lilly roils the obesity market

National associations that represent hospice owe an apology

Walensky prepares to leave CDC — and Congress — behind

Vivek Ramaswamy made waves in the debate, much as in biotech

Heart attack and stroke risk calculators need revising

How the first Native Hawaiian psychiatrist helped diversify medicine

Anesthesiologist group: stop taking Ozempic before surgery

In his State of the Union, Biden takes clear aim at 'Big Pharma'

focus

Kellogg’s is going to war over Mexico’s nutrition label rules

Amylyx ALS drug fails large clinical trial

Former medical device CEO who sold dummy, plastic parts convicted of fraud

How the drug

The problem with charging patients to message their doctors

Change Healthcare cyberattack prompts Medicare loan program

Wikipedia

explore

explore

entertainment